Guggenheim initiated coverage of NeoGenomics with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2025 | Buy → Neutral | BTIG Research | |
| 7/29/2025 | Outperform → Mkt Perform | William Blair | |
| 5/15/2025 | Neutral | Guggenheim | |
| 4/30/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 1/13/2025 | Buy → Hold | The Benchmark Company | |
| 12/10/2024 | $22.00 | Buy | Jefferies |
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: Stephens Annual Investment Conference in Nashville, TN Company presentation on Wednesday, November 19, at 1:00 pm CT, accessible here Piper Sandler 37th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 2, at 2:30 pm ET, accessible here Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializ
Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. NeoGenomics will also present on the progress of its NextGen (whole genome-based) MRD research program, as well as three additional posters highlighting the company's work in liquid biopsy and genomic profiling across solid tumo
Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025. Third Quarter 2025 Highlights As Compared To Third Quarter 2024 Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18%
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
SCHEDULE 13G/A - NEOGENOMICS INC (0001077183) (Subject)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025. Third Quarter 2025 Highlights As Compared To Third Quarter 2024 Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18%
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domesti
Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024 Consolidated revenue increased 10% to record $181 million Net loss increased 142% to $45 million including $20 million of impairment charges Adjusted EBITDA remained relatively flat at positive $11 million
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a
Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
BTIG Research downgraded NeoGenomics from Buy to Neutral
William Blair downgraded NeoGenomics from Outperform to Mkt Perform
Guggenheim initiated coverage of NeoGenomics with a rating of Neutral